| Indirubin |
NCT01735864 |
Completed |
Not Applicable |
Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment |
Psoriasis Vulgaris |
https://ClinicalTrials.gov/show/NCT01735864 |
| Indirubin |
NCT02088281 |
Completed |
Phase 2 |
Mechanistic Study of Indigo Naturalis in Treating Psoriasis |
Psoriasis Vulgaris |
https://ClinicalTrials.gov/show/NCT02088281 |
| Indirubin |
NCT01445886 |
Completed |
Phase 2|Phase 3 |
Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis |
Nail Psoriasis |
https://ClinicalTrials.gov/show/NCT01445886 |
| Indirubin |
NCT02200978 |
Enrolling by invitation |
Phase 4 |
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia |
Childhood Acute Promyelocytic Leukemia |
https://ClinicalTrials.gov/show/NCT02200978 |
| Indirubin |
NCT03614221 |
Recruiting |
Phase 2 |
Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis |
Atopic Dermatitis |
https://ClinicalTrials.gov/show/NCT03614221 |
| Indirubin |
NCT02669888 |
Completed |
Phase 2 |
Indigo Naturalis in Treating Atopic Dermatitis Topically |
Atopic Dermatitis |
https://ClinicalTrials.gov/show/NCT02669888 |
